MiR-140 promotes the progression of intracranial aneurysms by targeting BCL2L2. Issue 1 (23rd November 2022)

• Record Type: Journal Article
• Authors: Deng, Jun; Ning, Kangwen; Liu, Danhong; Wu, Dahua; Wan, Rongwen; Ge, Jinwen
• Is Part Of: NeuroReport. Volume 34:Issue 1(2023)
• Page Start: 38
• Page End: 45
• Publication Date: 2022-11-23
• Subjects: apoptosis -- BCL2L2 -- intracranial aneurysms -- miR-140 -- proliferation; Neurosciences -- Periodicals; Nervous system -- Periodicals; Neurophysiology -- Periodicals; Nervous System Diseases -- Periodicals; Nervous System Physiological Phenomena -- Periodicals; Neurosciences -- Periodicals; 616.805
• DOI: 10.1097/WNR.0000000000001856
• Languages: English
• ISSNs: 0959-4965

Abstract

Abstract : To investigate the role of miR-140/BCL2L2 axis on the formation of intracranial aneurysms. The expression of miR-140 in the serum of patients with intracranial aneurysms and healthy volunteers was detected. CCK-8 assay and Annexin V-FITC/PI double staining flow cytometry were used to evaluate the effect of miR-140 knockdown on the proliferation and apoptosis of human brain vascular smooth muscle cells (HBVSMCs). Meanwhile, the relationship between miR-140 and BCL2L2 was examined. MiR-140 was found to be upregulation in intracranial aneurysm patients. MiR-140 knock-out significantly inhibited the apoptosis of HBVSMCs and promoted cell proliferation. BCL2L2 was a direct target gene of miR-140 and suppressed its expression. Knockdown of miR-140 alleviates the development of intracranial aneurysms. MiR-140/BCL2L2 axis promotes the progression of intracranial aneurysms by regulating apoptosis of HBVSMCs. Therefore, miR-140 is a potential therapeutic target for intracranial aneurysms.